Publicaciones en las que colabora con JOSE LUIS PEDRAZ MUÑOZ (12)

2019

  1. Beneficial effects of n-3 polyunsaturated fatty acids administration in a partial lesion model of Parkinson's disease: The role of glia and NRf2 regulation

    Neurobiology of Disease, Vol. 121, pp. 252-262

2018

  1. Intranasal administration of TAT-conjugated lipid nanocarriers loading GDNF for Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 145-155

  2. The role of lipid nanoparticles and its surface modification in reaching the brain: An approach for neurodegenerative diseases treatment

    Current Drug Delivery, Vol. 15, Núm. 9, pp. 1218-1220

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

  2. Nanotechnology based approaches for neurodegenerative disorders: Diagnosis and treatment

    Drug and Gene Delivery to the Central Nervous System for Neuroprotection: Nanotechnological Advances (Springer International Publishing), pp. 57-87

2016

  1. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases

    Nanomedicine, Vol. 11, Núm. 10, pp. 1267-1285

  2. Intranasal administration of chitosan-coated nanostructured lipid carriers loaded with GDNF improves behavioral and histological recovery in a partial lesion model of Parkinson's disease

    Journal of Biomedical Nanotechnology, Vol. 12, Núm. 12, pp. 2220-2230

2015

  1. New Insights into Gene Delivery to Human Neuronal Precursor NT2 Cells: A Comparative Study between Lipoplexes, Nioplexes, and Polyplexes

    Molecular Pharmaceutics, Vol. 12, Núm. 11, pp. 4056-4066

  2. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687

2013

  1. In vivo administration of VEGF- and GDNF-releasing biodegradable polymeric microspheres in a severe lesion model of Parkinson's disease

    European Journal of Pharmaceutics and Biopharmaceutics, Vol. 85, Núm. 3 PART B, pp. 1183-1190

2007

  1. Long-term survival of encapsulated GDNF secreting cells implanted within the striatum of parkinsonized rats

    International Journal of Pharmaceutics, Vol. 343, Núm. 1-2, pp. 69-78